首页> 化学试剂> 其他化学试剂> 其他> ZSTK474，5MG，SML3194-5MG，Sigma

收藏产品

ZSTK474，5MG，SML3194-5MG，Sigma

销售价： ¥ 834.58 / 件

在线询价

优惠：请询价

订货号： 0BM1705

品牌型号： Sigma SML3194-5MG

货期：询货期

最小订货量： 1件

+ -

加入购物车

联系我们

400-920-3909

微信扫一扫，手机采购

精选商品

ITS液体培养基补充剂（100x），I3146-5ML，Sigma

销售价： ¥ 706.75

加入购物车

LookOut DNA Erase，250 mL，L8917-250ML

销售价： ¥ 670.73

加入购物车

F-12培养基,N4888-6X500ML,Sigma

销售价： ¥ 2367.14

加入购物车

潮霉素B，20ML，10843555001，Roche

销售价： ¥ 2550.13

加入购物车

NADPH，1G，10621706001，Roche

销售价： ¥ 27460.69

加入购物车

光溜海绵素C，10UG，X2628-10UG，Sigma

销售价： ¥ 4893.32

加入购物车

商品介绍
规格参数
包装参数

产品介绍 Product Description

General description

Potent antitumor activity by oral administration against murine solid tumors and human cancer xenografts

Biochem/physiol Actions

A novel s-triazine derivative, ZSTK474 [2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine], strongly inhibited the growth of tumor cells. A molecular target for ZSTK474 is PI3K. ZSTK474 directly inhibits PI3K activity more efficiently than the PI3K inhibitor LY294002. At concentrations of 1μM, ZSTK474 and LY2194002 reduced PI3K activity to 4.7% (95% confidence interval [CI] = 3.2% to 6.1%) and 44.6% (95% CI = 38.9% to 50.3%), respectively, of the untreated control level. Molecular modeling of the PI3K-ZSTK474 complex indicated that ZSTK474 could bind to the ATP-binding pocket of PI3K. ZSTK474 inhibited phosphorylation of signaling components downstream from PI3K, such as Akt and glycogen synthase kinase 3β, and mediated a decrease in cyclin D1 levels. ZSTK474 administered orally to mice had strong antitumor activity against human cancer xenografts without toxic effects in critical organs. Akt phosphorylation was reduced in xenograft tumors after oral administration of ZSTK474. ZSTK474 is a new PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in critical organs.
ZSTK474 is a reversible PI3K inhibitor. IC₅₀ 10-100 nM. Decreased the PDGF-dependent membrane ruffling of murine embryonic fibroblast cells, inhibited the phosphorylation of PI3K-downstream components, Akt and glycogen synthase kinase-3β, and decreased the cyclin D1 level.
ZSTK474 is an orally active, potent and selective, ATP-competitive inhibitor against class I phosphatidylinositol 3 kinase isoforms (PI3K IC50 in nM = 4.6/δ, 16/α, 44/β, 49/γ with = 10 μM ATP; mTOR IC50 >100 μM) with 27-fold selectivity for PI3Kα over DNA-PK. ZSTK474 inhibits PI3K-mediated signaling events in A549 cells in cultures (0.5 μM; Akt pSer473, GSK-3β pSer9, cyclinD1 expression) and induces tumor growth arrest or regression in mice in vivo (100, 200, or 400 mg/kg via daily p.o. against murine B16F10 melanoma or human A549 lung cancer, PC-3 prostate cancer, and WiDr colon cancer).

技术参数 Specifications

Quality Level	100
assay	≥98% (HPLC)
form	powder
color	white to beige
solubility	DMSO: 2 mg/mL, clear (warmed)
storage temp.	−20°C
SMILES string	FC(F)c1[n](c5c(n1)cccc5)c2nc(nc(n2)N4CCOCC4)N3CCOCC3
InChI	1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2
InChI key	HGVNLRPZOWWDKD-UHFFFAOYSA-N

长度(mm)
宽度(mm)
高度(mm)
重量(kg)